Wang Si-Si, Meng Zhao-Li, Zhang Yi-Wen, Yan Yi-Shuang, Li Ling-Bo
Department of Translational Medicine, The First Hospital of Jilin University, Changchun, China.
Aikang MedTech Co., Ltd., Shenzhen, China.
Front Neurol. 2024 Jul 10;15:1392984. doi: 10.3389/fneur.2024.1392984. eCollection 2024.
KANNO is a new human blood group that was recently discovered. The KANNO antigen shares the gene with the prion protein and the prion protein E219K polymorphism determines the presence or absence of the KANNO antigen and the development of anti-KANNO alloantibodies. These alloantibodies specifically react with prion proteins, which serve as substrates for conversion into pathological isoforms in some prion diseases and may serve as effective targets for resisting prion infection. These findings establish a potential link between the KANNO blood group and human prion disease via the prion protein E219K polymorphism. We reviewed the interesting correlation between the human gene's E219K polymorphism and the prion proteins it expresses, as well as human red blood cell antigens. Based on the immune serological principles of human blood cells, the prion protein E219K polymorphism may serve as a foundation for earlier molecular diagnosis and future drug development for prion diseases.
卡诺(KANNO)是最近发现的一种新的人类血型。卡诺抗原与朊病毒蛋白共享基因,朊病毒蛋白E219K多态性决定了卡诺抗原的存在与否以及抗卡诺同种抗体的产生。这些同种抗体与朊病毒蛋白特异性反应,在某些朊病毒疾病中,朊病毒蛋白作为转化为病理异构体的底物,可能成为抵抗朊病毒感染的有效靶点。这些发现通过朊病毒蛋白E219K多态性在卡诺血型与人类朊病毒疾病之间建立了潜在联系。我们综述了人类基因E219K多态性与其表达的朊病毒蛋白以及人类红细胞抗原之间的有趣关联。基于人类血细胞的免疫血清学原理,朊病毒蛋白E219K多态性可能为朊病毒疾病的早期分子诊断和未来药物开发奠定基础。